Navigation Links
Digital vs. Analog Mammography


Just as consumers today have to decide between analog and digital television sets, so, too, do physicians and radiology centers have to choose between analog and digital mammography units, with the latter rapidly gaining ground in imaging centers around the country.

As of late 2003, the U.S. Food and Drug Administration (FDA) had cleared four digital mammography units for clinical usethe Senographe 2000D Full-Field Digital Mammography systems, approved in January 2000 and manufactured and marketed by GE Health Systems; the SenoScan, approved in Sept 2001 and manufactured and marketed by Fischer Imaging; and the LORAD LDBI, approved in March 2002 and Hologic/Lorad Selenia Full Field Digital Mammography (FFDM) System, approved in October 2002, both manufactured and marketed by Lorad/Hologic. Fuji-Film Medical Systems is also pursuing a digital system.

Like analog mammography, digital mammography is basically an x-ray of the breast used for both screening and diagnosis. Patients notice no difference between the two forms, as the breast is squeezed between two plates and x-rays pass through the breast tissue.

Unlike traditional mammography, however, which uses film as both a receptor and a display for the image to produce static, fixed images, digital mammography uses detectors (similar to those found in digital cameras) that change the x-rays into electrical signals. These signals are then transferred to a digital receptor that converts the x-ray energy to numbers, processes the numbers, and produces an image that can be displayed on a monitor or printed on a high-resolution laser printer.

Digital detectors create an electronic image as pixels, either indirectly or directly. They use either charge-coupled devices (CCDs), flat-panel arrays or computed radiography cassettes. CCDs are self-scanning devices that provide an electronic readout of an image produced by a scintillator. Electrons, whose numbers are related to the image *produ
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog Liraglutide, Brings Patients to A1c Target
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Digital Analog Mammography
(Date:5/15/2008)...ire-FirstCall/ -- Schering-Plough,Corporation (NYS...reatment of,chronic hepatitis C virus (HCV) infect...al studies with PEGINTRON(TM) (peginterferon alfa-...erapy, as well as boceprevir, the,company,s invest...sented at,the 39th annual Digestive Disease Week (...
(Date:5/15/2008)...ance, May 15 /- Cerenis,Therapeutics ...any,developing HDL-related compounds for the treat...ay announced that it has completed a Phase I,clini...roduct candidates.,CER-002 is a peroxisome prolife...nist in development for the treatment of cardiovas...
(Date:5/15/2008)...e-FirstCall/ -- Novavax, Inc. (Nasdaq:,NVAX) today... Phase I/IIa,study of its pandemic influenza vacci.... Favorable interim results from the first phase o...healthy adult volunteers, were,reported in Decembe...ccine,is well tolerated and immunogenic at the 15 ...
(Date:5/15/2008)...ompares Genous, Boston Scientific,s ...us on Real-World Use of Genous, Stent,s Performanc...ate Dual-Antiplatelet ... -- OrbusNeich today announced,that multiple clini...008,support the use of the company,s Genous Bio-en...
Breaking Medicine Technology:Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 2Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 3Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 4Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 5Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 6Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 7Cerenis Therapeutics Completes Phase I Clinical Trial of CER-002 for Treatment of Cardiovascular Disease 2Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial 2Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial 3Multiple Clinical Data Presentations at EuroPCR 2008 Support Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) as Safe Alternative to Drug-Eluting Stents 2Multiple Clinical Data Presentations at EuroPCR 2008 Support Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) as Safe Alternative to Drug-Eluting Stents 3Multiple Clinical Data Presentations at EuroPCR 2008 Support Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) as Safe Alternative to Drug-Eluting Stents 4Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER 28R 29 Sirolimus eluting Coronary Stent Comp 186 1Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER 28R 29 Sirolimus eluting Coronary Stent Comp 186 2Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER 28R 29 Sirolimus eluting Coronary Stent Comp 186 3Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER 28R 29 Sirolimus eluting Coronary Stent Comp 186 4Large intensive care study reveals vital recommendations for treatment of brain injury patients 427 1Large intensive care study reveals vital recommendations for treatment of brain injury patients 427 21 5 million children could be saved 425 11 5 million children could be saved 425 2Genes Environment and Health Initiative invests in genetic studies environmental monitoring 239 1Genes Environment and Health Initiative invests in genetic studies environmental monitoring 239 2Genes Environment and Health Initiative invests in genetic studies environmental monitoring 239 3Genes Environment and Health Initiative invests in genetic studies environmental monitoring 239 4Genes Environment and Health Initiative invests in genetic studies environmental monitoring 239 5Genes Environment and Health Initiative invests in genetic studies environmental monitoring 239 6Genes Environment and Health Initiative invests in genetic studies environmental monitoring 239 7Genes Environment and Health Initiative invests in genetic studies environmental monitoring 239 8Genes Environment and Health Initiative invests in genetic studies environmental monitoring 239 9
(Date:5/15/2008)...ernor Paterson,s leadership in proposing prescript...Y, N.Y., May 15 /PRNewswire-USNewswire/ -- AARP st...in passing the Governor,s prescription,marketing r...that,pharmaceutical companies have over prescribin... books but the treatment they receive., The refor...
(Date:5/15/2008)... May 15, 2008 -- The Society for Cardiovascular A...d that it will hold its 2009 Annual Scientific Ses... The focused, collegial interventional cardiology ...h meeting time beginning in 2010. , The 2009 SCA...nterventional cardiology meeting of the spring for...
(Date:5/15/2008)...May 15 /PRNewswire-FirstCall/ -- (Nasdaq: WHRT, TS...day announced that, on May,12, 2008, it had receiv...t,the Company,s requests for continued listing on ...DAQ noted that the Company did not provide a,defin...term compliance with,the continued listing require...
(Date:5/15/2008)...May 15 /PRNewswire-FirstCall/ -- Pharmasset, Inc.,...company committed to,discovering, developing and c...ns, reported unaudited financial results for the s...set reported a net loss attributable,to common sto...or the,quarter ended March 31, 2008, as compared t...
Breaking Medicine News(10 mins):Health News:AARP Statement on Governor's Bill for Prescription Drug Marketing Reform and Transparency 2Health News:SCAI announces 2009 annual scientific sessions in Las Vegas 2Health News:WorldHeart Announces Possible Delisting Action by NASDAQ 2Health News:WorldHeart Announces Possible Delisting Action by NASDAQ 3Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 2Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 3Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 4Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 5Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 6Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 7Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 8
...inister Girija Prasad Koirala's sister-in-law and ...l, //battling jaundice, kidney problems and other ...75, has been admitted to Shahid Gangalal National ...the octogenarian premier himself had stayed for tr...
...ves to encourage healthy eating habits, teens in m...tables than in 1999, a new study reveals.// And th...it and vegetable intake is important for the preve... lead investigator and registered dietitian Nicole...
...h alcohol can lead to multiple health problems, in...he accuracy of this perception.// Many people also...o drink to excess are probably alcoholics. This ma...population in New Mexico reveals that, in fact, mo...
...ring pregnancy can range from the very serious Fet...y greater-occurring Fetal Alcohol// Spectrum Disor...ency, the beverage size and type, all appear to be...ey has found that nearly 80 percent of non-Indigen...
Other Medicine News:Health News:Nepal's Most Influential Woman 'Critically' Ill 2Health News:Today’s Teens Slacking on Fruit, Veggie Intak 2Health News:Excessive Drinking, Not Alcoholism, may Lead to Most Alcohol-Related Problems 2Health News:Risk Factors of Drinking Before, and During, Pregnancy 2
A sturdy, robust stool. Gas operated height adjustment for convenience.
Anterior Stromal Puncture Cannula, 25 g. For treatment of recurrent corneal erosion. Overall length 24 mm. 5/box.
Viscoelastic Cannula, 23 g. Angled. 7 mm angled tip cannula with unique hub that facilitates flow of viscoelastic material. Overall length 23 mm. 5/box.
Anterior Chamber Needle, 21 g., 8 mm from bend to tip. Overall length 25 mm. 5/box.
Medicine Products: